It looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in the coming months after backing from an FDA expert commit
Reviewers from the FDA have given Celltrion’s biosimilar of Roche’s blood cancer blockbuster Rituxan a glowing report ahead of a key meeting of its advisers tomorrow.
